Vorozole
- 1 September 1997
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 11 (3) , 245-250
- https://doi.org/10.2165/00002512-199711030-00007
Abstract
▲ Vorozole is a triazole derivative which binds to the cytochrome P450 moiety of aromatase, thus causing reversible inhibition of the enzyme. ▲ Plasma estradiol levels are reduced by about 90% in postmenopausal women treated with vorozole. ▲ Phase II clinical studies found vorozole to be an effective agent for the treatment of postmenopausal women with advanced breast cancer, achieving objective responses in up to 35% of patients. ▲ In 2 large phase III studies, vorozole 2.5 mg/day demonstrated favourable clinical efficacy compared with aminoglutethimide and megestrol. ▲ Vorozole improved patients’ quality of life to a greater extent than aminoglutethimide. ▲ Clinical trials to date indicate that the tolerability of vorozole is better than that of aminoglutethimide. Vorozole also appears to be at least as well tolerated as megestrol (although inappropriate bodyweight gain is more common in megestrol recipients). The most common adverse events with vorozole are hot flushes, and nausea, which are generally mild in severity. ▲ Vorozole is a triazole derivative which binds to the cytochrome P450 moiety of aromatase, thus causing reversible inhibition of the enzyme. ▲ Plasma estradiol levels are reduced by about 90% in postmenopausal women treated with vorozole. ▲ Phase II clinical studies found vorozole to be an effective agent for the treatment of postmenopausal women with advanced breast cancer, achieving objective responses in up to 35% of patients. ▲ In 2 large phase III studies, vorozole 2.5 mg/day demonstrated favourable clinical efficacy compared with aminoglutethimide and megestrol. ▲ Vorozole improved patients’ quality of life to a greater extent than aminoglutethimide. ▲ Clinical trials to date indicate that the tolerability of vorozole is better than that of aminoglutethimide. Vorozole also appears to be at least as well tolerated as megestrol (although inappropriate bodyweight gain is more common in megestrol recipients). The most common adverse events with vorozole are hot flushes, and nausea, which are generally mild in severity.Keywords
This publication has 13 references indexed in Scilit:
- Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.1997
- Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the ratCancer Chemotherapy and Pharmacology, 1996
- The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511The Journal of Steroid Biochemistry and Molecular Biology, 1995
- Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.1995
- Pharmacology of vorozoleThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- Inhibition of Peripheral Aromatization in the Male Cynomolgus Monkey by a Novel Nonsteroidal Aromatase Inhibitor (R 76713)*Journal of Clinical Endocrinology & Metabolism, 1991
- Comparative effects of the aromatase inhibitor R76713 and of its enantiomers R83839 and R83842 on steroid biosynthesis in vitro and in vivoThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- Endocrine and Antitumoral Effects of R76713 in RatsJournal of Enzyme Inhibition, 1990
- R 76713, a new specific non-steroidal aromatase inhibitorThe Journal of Steroid Biochemistry and Molecular Biology, 1989